Company profile
KARDIGAN, INC.
NASDAQ:KARDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DANICAMTIV | phase2 | — | 8 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07210723 | phase2_3 | recruiting | 2026-02-13 | 2027-09-01 | Kardigan, Inc. | A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy |
| NCT07771465 | phase3 | recruiting | 2026-08-26 | 2032-11-01 | Kardigan, Inc. | A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy |
| NCT06864104 | phase2 | completed | 2025-04-10 | 2026-01-12 | Kardigan, Inc. | A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL) |
| NCT07001800 | phase2_3 | recruiting | 2025-06-27 | 2028-08-31 | Kardigan, Inc. | Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study |
| NCT07511361 | phase2 | recruiting | 2026-06-23 | 2026-12-01 | Kardigan, Inc. | Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension |
FDA applications (0)
No records yet.